Shopping Cart
Remove All
Your shopping cart is currently empty
GRKs-IN-1 hydrochloride, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50=130 nM) and GRK5 (IC50=7.1 μM).GRKs-IN-1 hydrochloride is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine[1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $475 | Inquiry | Inquiry | |
| 2 mg | $758 | Inquiry | Inquiry | |
| 5 mg | $1,326 | Inquiry | Inquiry | |
| 10 mg | $2,083 | Inquiry | Inquiry | |
| 25 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder | |
| 100 mg | Inquiry | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $1,422 | Inquiry | Inquiry |
| Description | GRKs-IN-1 hydrochloride, Compound 14as, has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50=130 nM) and GRK5 (IC50=7.1 μM).GRKs-IN-1 hydrochloride is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine[1]. |
| Targets&IC50 | GRK2:30 nM, GRK5:7.1 μM |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O: 50 mg/mL, Sonication is recommended. DMSO: 250 mg/mL, Sonication is recommended. |
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL, Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.